Significance of YAP1-MAML2 rearrangement and GTF2I mutation in the diagnosis and differential diagnosis of metaplastic thymoma

Ann Med. 2023;55(2):2237040. doi: 10.1080/07853890.2023.2237040.

Abstract

Background: Metaplastic thymoma (MT) is a very uncommon thymoma type, with biphasic differentiation as one of its histological characteristics. This histological pattern, however, can also be mistaken for type A thymoma and the A component in type AB thymoma.

Methods: Postoperative specimens were collected from five MT and four type A thymomas with a retrospective analysis involving immunohistochemistry, fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS).

Results: The histological morphology of the MT overlapped with that of the type A thymoma. With immunostains, the former's spindle cell components expressed vimentin and EMA, but not CD20. In MT, 3/5 cases had the nuclear expression of YAP1. The spindle cell component of the type A thymoma was found to express CD20. In all five cases of MT, FISH detection revealed YAP1-MAML2 fusion, which was not found in any type A thymoma cases. NGS sequencing confirmed YAP1-MAML2 rearrangement in all five cases of MT, and mutations in POLE and HRAS were also found in two cases, respectively. GTF2I c.74146970 T > A mutations were found in all cases of type A thymoma, and HRAS and NRAS mutations were found in two cases, but no YAP1-MAML2 rearrangement was evident.

Conclusions: For the diagnosis and differential diagnosis of challenging cases, the YAP1-MAML2 rearrangement and GTF2I mutation were both significant molecular events specific to MT and type A thymoma, respectively.

Keywords: GTF2I mutation; Metaplastic thymoma; YAP1–MAML2 rearrangement; fluorescence in situ hybridization; next-generation sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diagnosis, Differential
  • Humans
  • In Situ Hybridization, Fluorescence
  • Mutation
  • Retrospective Studies
  • Thymoma*
  • Thymus Neoplasms*
  • Trans-Activators
  • Transcription Factors, TFII*
  • Transcription Factors, TFIII*

Substances

  • Transcription Factors, TFIII
  • GTF2I protein, human
  • Transcription Factors, TFII
  • MAML2 protein, human
  • Trans-Activators

Grants and funding

This study was supported by grants from the Natural Science Foundation of Liaoning (2021-MS-160, 2022-MS-218).